Which of these sounds like you?

60 and over, and the goal is staying capable

Getting winded when that is new is a question for a clinician before it is a question for a library. A change in what a flight of stairs costs is the kind of thing a doctor can investigate with a history and a test, and no research page can. Nothing below explains it, and nothing below is worth reading in place of that.

What has been studied in this population

The useful question is which trials recruited older adults on purpose. The pages linked below carry eight studies that set an entry floor at 60 or over, and seven of them have reported: healthy adults aged 64 to 81, adults aged 65 or older, women aged 64 to 85 with low femoral neck bone density, hip-fracture patients aged 65 or older and healthy adults aged 60 to 81 on the MK-677 page; healthy men over 60 and postmenopausal women on the ostarine page; and adults aged 60 to 85 on the SS-31 page. The eighth is a healthy-aging pilot in adults aged 65 to 80, registered and still recruiting, so it has no result to read.

The endpoints they chose were narrow, and they were not the same endpoint. Growth hormone output and body composition, bone turnover and femoral neck density, functional performance after a hip fracture, lean body mass and physical function, and mitochondrial energy production in skeletal muscle after a single infusion. A result from one of those is not a result about another.

Healthy for their age is not the whole of that group. Two of the MK-677 trials recruited healthy older adults, the ostarine trial recruited healthy men over 60 and postmenopausal women, and the SS-31 infusion study recruited adults aged 60 to 85, which its page files as its one healthy-aging readout. The rest recruited by a condition: low femoral neck bone density, a recent hip fracture, and in one pooled report functional impairment. Each page prints the words its own paper used, and a result measured in one of those groups is a result about that group.

What does not apply here

Rodent repair work does not become a human result by being read alongside an older body. The tissue-repair compounds in this library were tested in rats and mice, and the guides say so on their own faces. Age changes nothing about what that evidence can support.

The organ-named bioregulator set is not evidence about aging well either. Its hub page states that all but a handful of the retrieved work is cell culture and animal experiments, that one report in older adults exists for one compound and is an abstract from the originating group, and that no approved labelling exists for any of them.

Strength, balance and stamina in daily life were not the endpoints. Lean mass on a scan and an ATP measurement are laboratory quantities. Whether either one changes what a person can carry up a flight of stairs is a separate question, and these trials did not ask it.

Where to read the evidence

Five of the eight, including the bone-density and hip-fracture ones, sit in the trial table on the page asking whether MK-677 is a SARM. The trial in healthy men over 60 and postmenopausal women, whose primary endpoint was lean mass, is on the ostarine classification page. The infusion study in adults aged 60 to 85, and the pilot that has not reported, are on the SS-31 page. The short organ-named peptides, and the exact edge of their record, are on the bioregulator hub.

An athlete who cannot move the way they did

A recovery that has stalled is a question for the clinician treating the injury. Whether the first assessment was complete is answered by an examination and imaging, not by a literature search. What follows is about what got measured in animals and what a testing pool prohibits, which is a different question entirely.

What has been studied in this population

Animals, rather than injured athletes. The pentadecapeptide this question usually arrives attached to is described on its own page as studied almost entirely in rodents, and the thymosin fragment beside it carries a record of the same shape. What got measured was healing in an animal injury model, not return to sport in a person.

The one record that is solid for this reader is legal rather than clinical. Anti-doping status is documented, dated and citable in a way the efficacy data is not, and the classification pages name the listing document each time a compound appears on one.

What does not apply here

Inside a testing pool, evidence is the second question. The first is status, and a compound with encouraging animal data and a prohibited-list entry is not a close call. No amount of mechanism reading changes a sanction.

An injury model is a lesion made on purpose so that it can be measured. A human injury arrives with a load history, earlier damage and a rehabilitation plan attached, and none of that is in the model. The two are not the same population wearing different fur.

Mobility was not the endpoint. Tissue-level healing markers in an animal and the ability to sprint again are different measurements, and nothing in this library reports a trial that crossed from one to the other.

Where to read the evidence

The rodent record for the repair peptides is set out on the BPC-157 guide and the TB-500 guide. The difference between the two families this question tends to mix together is on SARMs versus peptides. Legal and anti-doping status, with the governing document named on each page, sits in the classification section.

A founder or operator running on empty

Tiredness that does not lift, week after week, is something a clinician can investigate and a research library cannot. A doctor can take a history, order bloods and rule things in and out. Nothing below does any of that, and nothing below is a reason to postpone it.

What has been studied in this population

Not this population, and the closest thing to it is a trial that reported nothing. A randomized trial of one compound in this library enrolled 563 patients with mild to moderate Alzheimer disease and ran for 12 months. It moved the marker it was built to move, by 72.9 percent at 12 months, and reported no significant difference against placebo on any of its four efficacy measures. Controlled human work aimed at a brain outcome does exist here. What it found is nothing.

The organ-named peptides, where this question usually lands, stop earlier than that. Cell culture, animal work, and a small number of uncontrolled human write-ups. On one of them the only human data sits inside a patent, which that page says in its own headline rather than further down.

What the record actually holds, on the page that holds the most of it: one independent DNA study, one in vitro head-to-head, and three small human reports, with the page's own table keeping solution chemistry, cell culture, rats and small uncontrolled human cohorts in separate rows. The human-derived row is induced neurons from elderly donor fibroblasts, and the page labels it as not a trial.

What does not apply here

A result in a dish is not a result about focus. Cognitive output, decision quality and work capacity under a chronic load were not the endpoints in any of that work, and a mechanism observed in cell culture does not cross the distance to a working week.

This library does not cover sleep, workload, alcohol or training. They sit outside what it publishes, and it is not going to gesture at a compound to fill the space where they belong.

Where to read the evidence

The 563-patient trial, and the rest of that compound's randomized record, are in the trial table on the page asking whether MK-677 is a SARM. The whole organ-named set, with what each record contains and where it stops, is on the bioregulator hub. The patent-bound human data is on the cortagen page, and the mixed cell, animal and small-cohort record is on the pinealon page.

Living with gut trouble and no clear diagnosis

Gut trouble that nobody has named yet is a question for a clinician, not for a compound page. Getting to a diagnosis takes a history, an examination and tests, and a doctor is the only route to any of the three. Nothing below substitutes for that, and nothing below is a reason to wait on it.

What has been studied in this population

Mice with a named, induced disease. The tripeptide this question arrives attached to was tested in mouse colitis and peritonitis models, in human cell lines, and on donated skin it barely crosses. Its page also records a 2025 case report of a bad reaction, and what an FDA review of the substance found.

The other candidate has the same shape of record. The repair peptide people reach for alongside it was studied almost entirely in rodents, gut models included, and its own guide opens by saying so.

What does not apply here

An unclear diagnosis is the exclusion, not the entry point. Every result above attaches to a named condition in a defined animal population. A symptom pattern that nobody has named yet matches none of those populations, so nothing in that record can be read across to it.

A regulatory review is not a trial result. What a regulator concluded about a substance and what a trial measured in patients are different documents answering different questions, and the page keeps them apart rather than blending them into one impression.

A case report is a single person, written up because something happened. It is evidence that an event occurred, never evidence of how often it occurs, and it says nothing about how anyone else would respond.

Where to read the evidence

The mouse, cell and regulator record is on the KPV page. The rodent repair literature, including the gut models, is on the BPC-157 guide. What a purity number on a certificate does and does not establish, which is a separate question that shows up fast here, is on the HPLC purity page.

Going through menopause

The route with the evidence behind it here is a clinician who can prescribe, order labs and take a history. This library does not carry that answer and is not going to start carrying it. What follows is the narrow slice it does cover, and that slice is not menopause.

What has been studied in this population

Two trials in this library enrolled postmenopausal women, and neither was about menopause. One recruited them alongside healthy men over 60 because body composition was the question, and its endpoints were lean body mass and physical function. The other enrolled 292 women aged 64 to 85 with low femoral neck bone density, and measured bone turnover and bone mineral density. Reading either as evidence about menopausal symptoms would be the exact mistake this page exists to prevent.

What does not apply here

Everything else, and this section is short because the record is. The best-evidenced route through menopausal symptoms is a prescription conversation, and it runs through drugs this library does not cover and is not going to start covering. Refusing to be the answer here is a decision, not a gap waiting for a page.

Where to read the evidence

Not on this site. The FDA publishes consumer material on menopause and the treatments approved for it, which anyone can open and check. The two pages here that report a trial in this population are the ostarine classification page, for body composition, and the page asking whether MK-677 is a SARM, for bone density. A third names the population only as one an approved label excludes, on the PT-141 legal status page. None of the three is about symptoms.